102 related articles for article (PubMed ID: 32005869)
1. Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Magnani M
Sci Rep; 2020 Jan; 10(1):1918. PubMed ID: 32005869
[TBL] [Abstract][Full Text] [Related]
2. Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Magnani M
Sci Rep; 2019 Aug; 9(1):11527. PubMed ID: 31395900
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Zhi J; Chen E; Major P; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1199-206. PubMed ID: 21409383
[TBL] [Abstract][Full Text] [Related]
6. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Kosugi C; Koda K; Ishibashi K; Yoshimatsu K; Tanaka S; Kato R; Kato H; Oya M; Narushima K; Mori M; Shuto K; Ishida H
Int J Colorectal Dis; 2018 Jun; 33(6):809-817. PubMed ID: 29484450
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: Effects of different intracranial volume correction methods on univariate sex differences in grey matter volume and multivariate sex prediction.
Sanchis-Segura C; Ibañez-Gual MV; Aguirre N; Cruz-Gómez ÁJ; Forn C
Sci Rep; 2020 Oct; 10(1):18937. PubMed ID: 33122664
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic activin A signaling.
Bauer J; Emon MAB; Staudacher JJ; Thomas AL; Zessner-Spitzenberg J; Mancinelli G; Krett N; Saif MT; Jung B
Sci Rep; 2020 Apr; 10(1):7606. PubMed ID: 32355318
[TBL] [Abstract][Full Text] [Related]
11. Author Correction: High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids.
Folkesson E; Niederdorfer B; Nakstad VT; Thommesen L; Klinkenberg G; Lægreid A; Flobak Å
Sci Rep; 2020 Nov; 10(1):20946. PubMed ID: 33239689
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
13. Author Correction: A recellularized human colon model identifies cancer driver genes.
Chen HJ; Wei Z; Sun J; Bhattacharya A; Savage DJ; Serda R; Mackeyev Y; Curley SA; Bu P; Wang L; Chen S; Cohen-Gould L; Huang E; Shen X; Lipkin SM; Copeland NG; Jenkins NA; Shuler ML
Nat Biotechnol; 2019 Jul; 37(7):820. PubMed ID: 31160724
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Lapeyre-Prost A; Hug de Larauze M; Chibaudel B; Garcia ML; Guering-Meyer V; Bouché O; Boucher E; Ychou M; Dauba J; Obled S; Lièvre A; Malka D; Faroux R; Bonnet I; Taieb J; André T;
Clin Colorectal Cancer; 2016 Sep; 15(3):250-6. PubMed ID: 26752558
[TBL] [Abstract][Full Text] [Related]
15. Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunity.
Moyer TJ; Kato Y; Abraham W; Chang JYH; Kulp DW; Watson N; Turner HL; Menis S; Abbott RK; Bhiman JN; Melo MB; Simon HA; Herrera-De la Mata S; Liang S; Seumois G; Agarwal Y; Li N; Burton DR; Ward AB; Schief WR; Crotty S; Irvine DJ
Nat Med; 2020 May; 26(5):804. PubMed ID: 32405059
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
18. Author Correction: Sex-based Differences in the Association between Body Composition and Incident Fracture Risk in Koreans.
Kim JH; Hong AR; Choi HJ; Ku EJ; Cho NH; Shin CS
Sci Rep; 2019 Nov; 9(1):18149. PubMed ID: 31776443
[TBL] [Abstract][Full Text] [Related]
19. Author Correction: Sex differences in dendritic spine density and morphology in auditory and visual cortices in adolescence and adulthood.
Parker EM; Kindja NL; Cheetham CEJ; Sweet RA
Sci Rep; 2020 Nov; 10(1):20080. PubMed ID: 33184373
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer.
Goerner M; Riemer-Hommel P
Onkologie; 2009 Nov; 32(11):647-52. PubMed ID: 19887868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
